{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:08:34Z","timestamp":1788858514551,"version":"build-2803163510"},"reference-count":90,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>Robust long\u2010term survival data have transformed the prognosis of metastatic melanoma. For combination therapy with immune checkpoint inhibitors (ICIs), 10\u2010year melanoma\u2010specific survival rates now exceed 50 %, and durable disease control is achievable in a substantial proportion of patients, including those with brain metastases.<\/jats:p>\n                  <jats:p>With increasing long\u2010term survival, chronic and late\u2010onset treatment\u2010related toxicities are becoming increasingly relevant. In particular, chronic immune\u2010related adverse events (irAEs) may persist after discontinuation of ICI therapy or emerge with delayed onset. These toxicities can significantly impair long\u2010term quality of life and often require ongoing management; endocrine toxicities, for example, may necessitate lifelong hormone replacement therapy.<\/jats:p>\n                  <jats:p>In addition to physical sequelae, survivors frequently experience psychosocial and financial burdens, difficulties returning to work, and concerns related to fertility and family planning. These multidimensional challenges highlight the growing importance of survivorship care in patients treated with ICIs.<\/jats:p>\n                  <jats:p>Systematic assessment of physical and psychosocial burden as well as health\u2010related quality of life, especially through patient\u2010reported outcomes, can support clinical decision\u2010making and individualized follow\u2010up strategies. Integrating these assessments into structured, multidisciplinary survivorship care models is essential to address the complex long\u2010term needs of melanoma survivors and to optimize outcomes beyond disease control.<\/jats:p>","DOI":"10.1111\/ddg.70486x","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:19:21Z","timestamp":1788855561000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer survivorship in malignant melanoma"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7134-1043","authenticated-orcid":false,"given":"Markus","family":"Reitmajer","sequence":"first","affiliation":[{"name":"Department of Dermatology University Hospital Tuebingen  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1339-6353","authenticated-orcid":false,"given":"Susanne","family":"Dugas\u2010Breit","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Center for Tumor Diseases (NCT) Heidelberg University Hospital  Heidelberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-5390","authenticated-orcid":false,"given":"Chiara L.","family":"Blomen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology University Medical Center Hamburg\u2010Eppendorf (UKE) Hamburg Germany Fleur Hiege Center for Skin Cancer Research University Medical Center Hamburg\u2010Eppendorf (UKE)  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin corporate member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus V.","family":"Heppt","sequence":"additional","affiliation":[{"name":"Department of Dermatology Uniklinikum Erlangen Friedrich\u2010Alexander\u2010University Erlangen\u2010N\u00fcrnberg (FAU)  Erlangen Germany"},{"name":"Comprehensive Cancer Center Erlangen\u2010European Metropolitan Area of Nuremberg (CCC ER\u2010EMN) Erlangen Germany Bavarian Cancer Research Center (BZKF) Uniklinikum Erlangen Friedrich\u2010Alexander\u2010University Erlangen\u2010N\u00fcrnberg (FAU)  Erlangen Germany"},{"name":"Dermpath M\u00fcnchen Laboratory for Dermatopathology Oral Pathology and Molecular Pathology  Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Sachse","sequence":"additional","affiliation":[{"name":"Department of Dermatology Allergology and Phlebology Bremerhaven Reinkenheide  Bremerhaven Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madlen","family":"H\u00f6rold","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research Medical Faculty Otto von Guericke University Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[{"name":"Skin Cancer Center at the University Cancer Centre Dresden and National Center for Tumor Diseases  Dresden Germany"},{"name":"Department of Dermatology Faculty of Medicine and University Hospital Carl Gustav Carus Technische Universit\u00e4t Dresden  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Regensburg  Regensburg Germany"},{"name":"Department of Dermatology University Hospital and Faculty of Medicine Martin Luther University Halle\u2010Wittenberg  Halle (Saale) Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-8219","authenticated-orcid":false,"given":"Christian","family":"Apfelbacher","sequence":"additional","affiliation":[{"name":"Institute of Social Medicine and Health Systems Research Medical Faculty Otto von Guericke University Magdeburg  Magdeburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Schilling","sequence":"additional","affiliation":[{"name":"Department of Oncological Rehabilitation Asklepios Nordseeklinik Westerland, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"von den Berg","sequence":"additional","affiliation":[{"name":"Department of Oncological Rehabilitation Asklepios Klinik Triberg  Triberg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4044-9094","authenticated-orcid":false,"given":"Frank","family":"Meiss","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Center \u2013 University of Freiburg Faculty of Medicine University of Freiburg  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Essen  Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6185-4945","authenticated-orcid":false,"given":"Andrea","family":"Forschner","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Tuebingen  Tuebingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"e_1_2_12_2_1","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller KD","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00761-021-00988-7","article-title":"Krebspr\u00e4valenz in Deutschland 2017","volume":"27","author":"Arndt V","year":"2021","journal-title":"Der Onkologe"},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jnci\/djab223","article-title":"Survivorship for Individuals Living With Advanced and Metastatic Cancers: National Cancer Institute Meeting Report","volume":"114","author":"Mollica MA","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-471752","article-title":"Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent Multinational Association of Supportive Care in Cancer\u2010ASCO Standards and Practice Recommendations","volume":"45","author":"Jefford M","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"e_1_2_12_6_1","unstructured":"LonkoA.Empfehlungspapier.https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/N\/Nationaler_Krebsplan\/Empfehlungspapier_UAG_Versorgungsmodelle_AG_LONKO_bf.pdf. (Last accessed on February 15 2026)."},{"issue":"1","key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10\u2010Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma","volume":"392","author":"Wolchok JD","year":"2025","journal-title":"N Engl J Med"},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10\u2010year follow\u2010up of the phase III KEYNOTE\u2010006 study","volume":"35","author":"Long GV","year":"2024","journal-title":"Ann Oncol"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(24)00735-6","article-title":"Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7\u2010year follow\u2010up of a multicentre, open\u2010label, randomised, phase 2 study","volume":"26","author":"Long GV","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"e_1_2_12_10_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor\u2010associated immune\u2010related adverse events (irAEs) terminology","volume":"11","author":"Naidoo J","year":"2023","journal-title":"J Immunother Cancer"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic Immune\u2010Related Adverse Events Following Adjuvant Anti\u2010PD\u20101 Therapy for High\u2010risk Resected Melanoma","volume":"7","author":"Patrinely JR","year":"2021","journal-title":"JAMA Oncol"},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended Follow\u2010Up of Chronic Immune\u2010Related Adverse Events Following Adjuvant Anti\u2010PD\u20101 Therapy for High\u2010Risk Resected Melanoma","volume":"6","author":"Goodman RS","year":"2023","journal-title":"JAMA Netw Open"},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/ddg.15712","article-title":"Psychosocial distress and persistent adverse events in long\u2010term survivors of stage IV melanoma \u2013 a cross\u2010sectional questionnaire study","volume":"23","author":"Reitmajer M","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"issue":"8","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006500","article-title":"Chronic immune\u2010related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review","volume":"11","author":"Barron CC","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"7","key":"e_1_2_12_15_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008591","article-title":"Chronic immune\u2010related adverse events arising from immune checkpoint inhibitors: an update","volume":"12","author":"Fletcher K","year":"2024","journal-title":"J Immunother Cancer"},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2024.102311","article-title":"Chronic gastrointestinal immune\u2010related adverse events in patients exposed to immune checkpoint inhibitors","volume":"48","author":"Jeay M","year":"2024","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"e_1_2_12_17_1","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200314","article-title":"Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities","volume":"11","author":"Rossi S","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"e_1_2_12_18_1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamadermatol.2025.0025","article-title":"Characterizing Chronic Cutaneous Immune\u2010Related Adverse Events Following Immune Checkpoint Inhibitors","volume":"161","author":"Fletcher KA","year":"2025","journal-title":"JAMA dermatology"},{"key":"e_1_2_12_19_1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune\u2010checkpoint inhibitors: long\u2010term implications of toxicity","volume":"19","author":"Johnson DB","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"e_1_2_12_20_1","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant Dabrafenib plus Trametinib in Stage III BRAF\u2010Mutated Melanoma","volume":"377","author":"Long GV","year":"2017","journal-title":"N Engl J Med"},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1200\/JCO.2025.43.16_suppl.9577","article-title":"Financial toxicity and employment outcomes in people with melanoma receiving adjuvant therapies","volume":"43","author":"Lai\u2010Kwon JE","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_22_1","unstructured":"Deutsche Dermatologische Gesellschaft DDG.S3\u2010Leitlinie Diagnostik Therapie und Nachsorge des Melanoms. AWMF\u2010Register Nr. 032\u2010024OL. 05.05.2024 Updated 07.2020 https:\/\/register.awmf.org\/de\/leitlinien\/detail\/032\u2010024OL(Last accessed on March 27 2024)."},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100248","article-title":"Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy","volume":"6","author":"Hassel JC","year":"2021","journal-title":"ESMO Open"},{"key":"e_1_2_12_24_1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ijwd.2016.12.004","article-title":"Prognosis for women diagnosed with melanoma during, before, or after pregnancy: Weighing the evidence","volume":"3","author":"Todd SP","year":"2017","journal-title":"Int J Womens Dermatol"},{"key":"e_1_2_12_25_1","first-page":"479","article-title":"[Fertility preservation in patients with melanoma\u2010a huge relief for those affected]","volume":"74","author":"Berking C","year":"2023","journal-title":"Dermatologie (Heidelb)"},{"key":"e_1_2_12_26_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103501","article-title":"Advanced stage melanoma during pregnancy: recommendations from a retrospective, multicentre, registry\u2010based study","volume":"89","author":"Borgers JSW","year":"2025","journal-title":"EClinicalMedicine"},{"key":"e_1_2_12_27_1","doi-asserted-by":"crossref","first-page":"7770","DOI":"10.1038\/s41598-025-91476-0","article-title":"Pharmacovigilance analysis of immune checkpoint inhibitor\u2010related reproductive adverse effects based on the FDA adverse event reporting system","volume":"15","author":"K\u00f6yl\u00fc B","year":"2025","journal-title":"Sci Rep"},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/14737140.2024.2372337","article-title":"Current practices in oncofertility counseling: updated evidence on fertility preservation and post\u2010treatment pregnancies in young women affected by early breast cancer","volume":"24","author":"Arecco L","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility Preservation in People With Cancer: ASCO Guideline Update","volume":"43","author":"Su HI","year":"2025","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1055\/a-0611-5549","article-title":"Fertility Preservation for Patients with Malignant Disease. Guideline of the DGGG, DGU and DGRM (S2k\u2010Level, AWMF Registry No.\u2009015\/082, November 2017) \u2013 Recommendations and Statements for Girls and Women","volume":"78","author":"Dittrich R","year":"2018","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"e_1_2_12_31_1","first-page":"420","article-title":"Reproductive impact of immune checkpoint inhibitor therapy in women with melanoma","volume":"6","author":"Rhodes Q","year":"2025","journal-title":"F S Rep"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter SM","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.3390\/cancers17213528","article-title":"Melanoma in Women of Reproductive Age: From Awareness and Prevention to Pregnancy\u2010Associated Management","volume":"17","author":"R\u00f3\u017ca\u0144ska M","year":"2025","journal-title":"Cancers (Basel)"},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s11764-020-00869-9","article-title":"Quality of life in \"chronic\" cancer survivors: a meta\u2010analysis","volume":"14","author":"Firkins J","year":"2020","journal-title":"J Cancer Surviv"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2024.116720","article-title":"Exploring the measurement of health related quality of life and broader instruments: A dimensionality analysis","volume":"346","author":"Heijdra Suasnabar JM","year":"2024","journal-title":"Soc Sci Med"},{"key":"e_1_2_12_36_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.116149","article-title":"Characteristics and quality of life of nine\u2010year survivors with metastatic melanoma treated with pembrolizumab beyond second\u2010line therapy","volume":"233","author":"Dugas\u2010Breit S","year":"2026","journal-title":"Eur J Cancer"},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12955-021-01722-y","article-title":"Translation and adaptation of the German version of the Veterans Rand\u201036\/12 Item Health Survey","volume":"19","author":"Buchholz I","year":"2021","journal-title":"Health Qual Life Outcomes"},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s11136-020-02688-y","article-title":"Psychometric properties of the EQ\u20105D\u20105L: a systematic review of the literature","volume":"30","author":"Feng YS","year":"2021","journal-title":"Qual Life Res"},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jval.2019.02.004","article-title":"PROMIS(\u00ae) Adult Health Profiles: Efficient Short\u2010Form Measures of Seven Health Domains","volume":"22","author":"Cella D","year":"2019","journal-title":"Value Health"},{"key":"e_1_2_12_40_1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ\u2010C30 health\u2010related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte S","year":"2019","journal-title":"Eur J Cancer"},{"key":"e_1_2_12_41_1","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12955-018-0920-0","article-title":"Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire","volume":"16","author":"Leeuwen M","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"e_1_2_12_42_1","first-page":"139","article-title":"Measuring quality of life in patients with melanoma: development of the FACT\u2010melanoma subscale","volume":"3","author":"Cormier JN","year":"2005","journal-title":"J Support Oncol"},{"key":"e_1_2_12_43_1","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/cncr.32692","article-title":"Development of the Functional Assessment of Cancer Therapy\u2010Immune Checkpoint Modulator (FACT\u2010ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs","volume":"126","author":"Hansen AR","year":"2020","journal-title":"Cancer"},{"key":"e_1_2_12_44_1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejca.2016.10.008","article-title":"A systematic review examining factors influencing health related quality of life among melanoma cancer survivors","volume":"69","author":"Hamel JF","year":"2016","journal-title":"Eur J Cancer"},{"key":"e_1_2_12_45_1","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/S1470-2045(24)00338-3","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325\u2010MG\/KEYNOTE\u2010054): long\u2010term, health\u2010related quality\u2010of\u2010life results from a double\u2010blind, randomised, controlled, phase 3 trial","volume":"25","author":"B\u00fchrer E","year":"2024","journal-title":"Lancet Oncol"},{"key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2022.08.004","article-title":"Adjuvant pembrolizumab versus placebo in resected high\u2010risk stage II melanoma: Health\u2010related quality of life from the randomized phase 3 KEYNOTE\u2010716 study","volume":"176","author":"Khattak MA","year":"2022","journal-title":"Eur J Cancer"},{"key":"e_1_2_12_47_1","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five\u2010Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin J","year":"2019","journal-title":"N Engl J Med"},{"key":"e_1_2_12_48_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.005","article-title":"Impact of immune checkpoint inhibitors and targeted therapy on health\u2010related quality of life of people with stage III and IV melanoma: a mixed\u2010methods systematic review","volume":"184","author":"Lai\u2010Kwon J","year":"2023","journal-title":"Eur J Cancer"},{"key":"e_1_2_12_49_1","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.21873\/anticanres.13387","article-title":"Long\u2010Term Quality of Life of Melanoma Survivors Is Comparable to that of the General Population","volume":"39","author":"Heino PJ","year":"2019","journal-title":"Anticancer Res"},{"key":"e_1_2_12_50_1","first-page":"439","volume-title":"Handbook of Quality of Life in Cancer","author":"Saw RPM","year":"2022"},{"key":"e_1_2_12_51_1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health\u2010related quality of life of long\u2010term advanced melanoma survivors treated with anti\u2010CTLA\u20104 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout AH","year":"2021","journal-title":"Acta Oncol"},{"key":"e_1_2_12_52_1","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1007\/s11136-017-1532-6","article-title":"Comparison of quality of life among long\u2010term melanoma survivors and non\u2010melanoma controls: a cross\u2010sectional study","volume":"26","author":"Vogel RI","year":"2017","journal-title":"Qual Life Res"},{"key":"e_1_2_12_53_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2023.6158","article-title":"Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma","volume":"160","author":"Mahama AN","year":"2024","journal-title":"JAMA Dermatol"},{"key":"e_1_2_12_54_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116440","article-title":"Depression, anxiety and quality of life in long\u2010term survivors of malignant melanoma: a register\u2010based cohort study","volume":"10","author":"Beutel ME","year":"2015","journal-title":"PLoS One"},{"key":"e_1_2_12_55_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pon.4236","article-title":"Quality of life in patients with skin tumors: the mediator role of body image and social support","volume":"26","author":"Pereira MG","year":"2017","journal-title":"Psychooncology"},{"issue":"2","key":"e_1_2_12_56_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/ddg.15560","article-title":"Employment, work ability and sick leave in melanoma patients within the first year of diagnosis","volume":"23","author":"Dugas\u2010Breit S","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_57_1","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1007\/s11136-020-02464-y","article-title":"Patient\u2010reported outcomes in melanoma survivors at 1, 3 and 5 years post\u2010diagnosis: a population\u2010based cross\u2010sectional study","volume":"29","author":"Lisy K","year":"2020","journal-title":"Qual Life Res"},{"key":"e_1_2_12_58_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11764-020-00862-2","article-title":"Long\u2010term work retention after treatment for cancer: a systematic review and meta\u2010analysis","volume":"14","author":"Boer AG","year":"2020","journal-title":"J Cancer Surviv"},{"key":"e_1_2_12_59_1","doi-asserted-by":"crossref","DOI":"10.1002\/pon.70335","article-title":"Gender Differences in Quality of Life and Psycho\u2010Oncological Needs During the First Year After Melanoma Diagnosis","volume":"34","author":"Dugas\u2010Breit S","year":"2025","journal-title":"Psychooncology"},{"key":"e_1_2_12_60_1","first-page":"1231","article-title":"Noncancer life stresses in newly diagnosed cancer","volume":"16","author":"Lehto US","year":"2008","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_61_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066800","article-title":"Screening for distress in routine oncological care\u2010a survey in 520 melanoma patients","volume":"8","author":"Loquai C","year":"2013","journal-title":"PLoS One"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11764\u2010025\u201001851\u2010z"},{"key":"e_1_2_12_63_1","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ijc.34152","article-title":"Late effects, long\u2010term problems and unmet needs of cancer survivors","volume":"151","author":"Schmidt ME","year":"2022","journal-title":"Int J Cancer"},{"key":"e_1_2_12_64_1","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/0284186X.2023.2168215","article-title":"Chronic fatigue in long\u2010term survivors of Hodgkin's lymphoma after contemporary risk\u2010adapted treatment","volume":"62","author":"Eikeland SA","year":"2023","journal-title":"Acta Oncol"},{"issue":"1","key":"e_1_2_12_65_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3390\/nu18010040","article-title":"Investigating Chronic Toxicity, Diet, Patient\u2010Reported Outcomes and the Microbiome in Immunotherapy\u2010Treated Metastatic Melanoma Survivors: A New Frontier","volume":"18","author":"Robert M","year":"2025","journal-title":"Nutrients"},{"key":"e_1_2_12_66_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcskn.2025.100466","article-title":"Needs, distress, state\u2010of\u2010health and quality\u2010of\u2010life in survivors of stage III melanoma: Results from the cross\u2010sectional MESSAGE study","volume":"3","author":"Skoda EM","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"e_1_2_12_67_1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00756338","article-title":"Assessing levels of adaptive functioning: The Role Functioning Scale","volume":"29","author":"Goodman SH","year":"1993","journal-title":"Community Ment Health J"},{"key":"e_1_2_12_68_1","first-page":"2693","article-title":"A qualitative study investigating Australian cancer service outpatients' experience of distress screening and management: what is the personal relevance, acceptability and improvement opportunities from patient perspectives?","volume":"30","author":"McCarter K","year":"2022","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_69_1","first-page":"1","article-title":"Overcoming toxicity challenges in immune checkpoint inhibitor treatment of high\u2010risk metastatic cancers","volume":"26","author":"Nalabothu R","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"e_1_2_12_70_1","first-page":"321","article-title":"Real\u2010world management of patients with complete response under immune\u2010checkpoint inhibition for advanced melanoma","volume":"23","author":"Reitmajer M","year":"2025","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_12_71_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.073","article-title":"LBA61 Early discontinuation of anti\u2010PD\u20101 therapy upon achieving a complete or partial response in patients with metastatic melanoma: The multicentre prospective Safe Stop Trial","volume":"36","author":"Joode KD","year":"2025","journal-title":"Annals of Oncology"},{"key":"e_1_2_12_72_1","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open\u2010label phase 3 study (KEYNOTE\u2010006)","volume":"390","author":"Schachter J","year":"2017","journal-title":"Lancet"},{"key":"e_1_2_12_73_1","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.20672","article-title":"Survival after cessation of immunotherapies in melanoma: A systematic review and meta\u2010analysis","volume":"39","author":"Mayer KE","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_2_12_74_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105833","article-title":"Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure","volume":"10","author":"Silva IP","year":"2025","journal-title":"ESMO Open"},{"key":"e_1_2_12_75_1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1524945","article-title":"Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta\u2010analysis","volume":"16","author":"Lallas K","year":"2025","journal-title":"Front Immunol"},{"key":"e_1_2_12_76_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2023.6158","article-title":"Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma","volume":"160","author":"Mahama AN","year":"2024","journal-title":"JAMA Dermatology"},{"key":"e_1_2_12_77_1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1007\/s11912-024-01541-6","article-title":"For the Long Haul: Management of Long\u2010Term Survivors after Melanoma Systemic Therapy","volume":"26","author":"Silverstein J","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"e_1_2_12_78_1","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12885-023-10759-9","article-title":"Oncological healthcare providers' perspectives on appropriate melanoma survivorship care: a qualitative focus group study","volume":"23","author":"Kamminga NCW","year":"2023","journal-title":"BMC Cancer"},{"key":"e_1_2_12_79_1","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/pon.4290","article-title":"Systematic review of psychosocial outcomes for patients with advanced melanoma","volume":"26","author":"Dunn J","year":"2017","journal-title":"Psychooncology"},{"key":"e_1_2_12_80_1","doi-asserted-by":"crossref","DOI":"10.2196\/37539","article-title":"The Achieving Self\u2010directed Integrated Cancer Aftercare Intervention for Detection of Recurrent and Second Primary Melanoma in Survivors of Melanoma: Pilot Randomized Controlled Trial","volume":"8","author":"Murchie P","year":"2022","journal-title":"JMIR Cancer"},{"key":"e_1_2_12_81_1","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1186\/s12885-021-08959-2","article-title":"Achieving integrated self\u2010directed Cancer aftercare (ASICA) for melanoma: how a digital intervention to support total skin self\u2010examination was used by people treated for cutaneous melanoma","volume":"21","author":"Reilly F","year":"2021","journal-title":"BMC Cancer"},{"key":"e_1_2_12_82_1","first-page":"4849","article-title":"\"Melanoma: Questions and Answers.\" Development and evaluation of a psycho\u2010educational resource for people with a history of melanoma","volume":"24","author":"Kasparian NA","year":"2016","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_83_1","first-page":"9587","article-title":"Feasibility, acceptability, and utility of a nurse\u2010led survivorship program for people with metastatic melanoma (MELCARE)","volume":"30","author":"Lai\u2010Kwon J","year":"2022","journal-title":"Support Care Cancer"},{"key":"e_1_2_12_84_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-015195","article-title":"Psychoeducational intervention for people at high risk of developing another melanoma: a pilot randomised controlled trial","volume":"7","author":"Dieng M","year":"2017","journal-title":"BMJ Open"},{"key":"e_1_2_12_85_1","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1200\/JCO.2016.68.2278","article-title":"Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial","volume":"34","author":"Dieng M","year":"2016","journal-title":"J Clin Oncol"},{"key":"e_1_2_12_86_1","first-page":"412","article-title":"[Survivorship care plans for cancer patients: the importance of risk stratification, self\u2010management and health literacy in the age of digital care]","volume":"65","author":"Mehnert\u2010Theuerkauf A","year":"2022","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"e_1_2_12_87_1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","volume":"51","author":"Campbell KL","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"e_1_2_12_88_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2519\/jospt.2023.11251","article-title":"Which Exercise Approaches Work for Relieving Cancer\u2010Related Fatigue? A Network Meta\u2010analysis","volume":"53","author":"Dong B","year":"2023","journal-title":"J Orthop Sports Phys Ther"},{"key":"e_1_2_12_89_1","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325100","article-title":"The effects of aerobic exercise in patients with cancer\u2010related fatigue: A systematic review and meta\u2010analysis","volume":"20","author":"Wang T","year":"2025","journal-title":"PLoS One"},{"key":"e_1_2_12_90_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO\u20105 Well\u2010Being Index: a systematic review of the literature","volume":"84","author":"Topp CW","year":"2015","journal-title":"Psychother Psychosom"},{"key":"e_1_2_12_91_1","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and Reliability of the US National Cancer Institute's Patient\u2010Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO\u2010CTCAE)","volume":"1","author":"Dueck AC","year":"2015","journal-title":"JAMA Oncol"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70486x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.70486x","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.70486x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:21:41Z","timestamp":1788855701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.70486x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/ddg.70486x"],"URL":"https:\/\/doi.org\/10.1111\/ddg.70486x","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"2026-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}